AMD diagnostic imaging
Patients are unaware they have a ticking time bomb in their eyes
Sean Henahan
Published: Tuesday, March 28, 2017
Patients are unaware they have a ticking time bomb in their eyesICG angiography Why not use ICG angiography to follow patients? That approach is expensive, invasive, time consuming, resource intensive, and until recently, such cases didn't have an intervention, he noted. Rather, Dr Rosenfeld and colleagues used a novel swept source OCT angiography system to look for subclinical CNV. The prototype from Carl Zeiss Meditec performed a 3mm X 3mm rraster scan centered on the fovea and repeated each B-scan 4 times, with 300 A-scans per B-scan, and 300 B-scan positions, for a total of 360,000 A-scans. Using a special decorrelation algorithms, the B-scans were compiled to provide en face flow images of the retina and choroid. The optical microangiographic approach known as OMAG provided provided the microvascular flow information and different layers were segmented, which included the whole retina, the inner or superficial retina layer or plexus, the middle or deep retinal plexus, and the outer avascular retinal layer. Another layer from the outer retinal layer to the choriocapillaris, known as the ORCC layer, was also created since this is where most of the choroidal neovascularization can be found. Subsequent clinical research (Ophthalmology, Roisman et al, Volume 123, Issue 6, 1309–1319) confirmed that the system could detect CNV lesions before they started leaking. Subsequent follow-up of 103 patients with wet AMD in one eye and dry AMD in the other revealed a prevalence of about 18% for these subclinical lesions, with an estimated rate of conversion to exudation of about 16% at one year, but longer follow-up is underway. “This is a new stage of non-exudative AMD. We call it non-exudative neovascular AMD. I think we can find these patients easily with SS-OCTA and we need to follow them closely. Ongoing studies are looking at prevalence, incidence, and onset of exudation. For now, in addition to close follow-up, we do not recommend anti-VEGF treatment,” he concluded. “I never treat asymptomatic patients. I educate my patients, I emphasize the need for vision monitoring at home, and I enlist them to be stewards of their own vision. In addition, if we start treatment in the absence of fluid, what’s our endpoint?,” Rosenfeld stated. prosenfeld@med.miami.edu
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.